Abivax

Contributing Author

Recent Articles by Abivax

Nov-03	Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis ABVX GlobeNewswire
Oct-06	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies ABVX GlobeNewswire
Oct-05	Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data ABVX GlobeNewswire
Sep-29	Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting ABVX GlobeNewswire
Sep-23	Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting ABVX GlobeNewswire
Sep-12	Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review ABVX GlobeNewswire
Sep-08	Abivax Presents First Half 2025 Financial Results ABVX GlobeNewswire
Jul-28	Abivax Announces Closing of $747.5 Million Public Offering ABVX GlobeNewswire
Jul-25	Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M) ABVX GlobeNewswire
Jul-24	Abivax announces trading resumption of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-24	Abivax Announces Pricing of $650M (554M) Public Offering of American Depositary Shares ABVX GlobeNewswire
Jul-24	Abivax announces temporary trading halt of its ordinary shares on Euronext Paris ABVX GlobeNewswire
Jul-23	Abivax Announces Launch of Public Offering ABVX GlobeNewswire
Jul-22	Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis ABVX GlobeNewswire
Jun-11	Abivax Announces Results of its June 6, 2025 Annual General Meeting ABVX GlobeNewswire
Jun-02	Abivax Presents First Quarter 2025 Financial Results ABVX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.